Overview


According to FutureWise analysis, the market for gynecology drugs in 2023 is US$ 28.16 billion, and is expected to reach US$ 46.32 billion by 2031 at a CAGR of 6.42%.

Gynecological ailments represent a wide range of divergent medical conditions, which are pertaining to the reproductive system of the female body. As a result, gynecological illnesses have a variety of conditions concerning the functioning of the ovaries, uterus and appendages. There are certain gynecological drugs market trends that are being demonstrated over the past few years. It has been observed that the acceptance of gynecology drugs has been pushing the market. Shifts in the lifestyles of women worldwide has pushed for greater improvements in their healthcare needs. A growing consciousness about good health, nutrition and overall well-being, has contributed to the rise in the demand for innovative gynecological treatments. Such opportunities have created inroads for drug manufacturers to establish better gynecological therapeutics that would deliver positive efficacy as well as minimal side-effects. Moreover, attributes such as revitalized economic growth and a rise in the geriatric female population are projected to boost the gynecology drugs market size. Segmentation-wise, the market has been fragmented into therapeutics which is bifurcated into hormonal and non-hormonal therapy. The segment for non-hormonal therapy is anticipated to account for the largest market share during the forecast time frame, due to the latest product development, productive qualities in the products, as well as boost in the acceptance of such products. Furthermore, minimal usage of hormonal products owing to the risk of breast cancer has garnered considerable demand for pharmaceutical products that are non-hormonal. In the case of the indication segment, the market has been categorized based on various conditions ranging from menopausal disorder, gynecology cancers, contraception, gynecology infections, female infertility, polycystic ovary syndrome and others. Based on the type of distribution channel, the market has been divided into retail, hospital and online pharmacies. Market intelligence has predicted that online pharmacies are shown to prosper at a high CAGR in the forecast time span, since there is a preference for online pharmacies and a boost in the volume of people who use the internet.

  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Amgen Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Lupin Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Johnson and Johnson
  • Bayer AG
  • Allergan Plc
  • Merck & Co.
  • Pfizer, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Therapeutics

  • Hormonal Therapy
    • Estrogen Therapy
    • Progestin Therapy
    • Combination Therapy
    • Thyroid Replacement Therapy
    • Parathyroid Hormone Therapy
    • Others
  • Non-hormonal Therapy
    • Anti-Infective Agents
    • Antineoplastic Agents
    • Anti-inflammatory Agents
    • Others

By Indication

  • Gynecology Cancers
  • Endometriosis
  • Female Infertility
  • Menopausal Disorder
  • Gynecology Infections
  • Polycystic Ovary Syndrome
  • Contraception (Birth Control)
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the gynecology drugs market by therapeutics, by indication, by distribution channel and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Gynecology Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Gynecology Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Gynecology Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Gynecology Drugs Market, By Therapeutics Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hormonal Therapy
         1.1.Estrogen Therapy
         1.2.Progestin Therapy
         1.3.Combination Therapy
         1.4.Thyroid Replacement Therapy
         1.5.Parathyroid Hormone Therapy
         1.6.Others
        2. Non-hormonal Therapy
         2.1.Anti-Infective Agents
         2.2. Antineoplastic Agents
         2.3.Anti-inflammatory Agents
         2.4.Others

  • 8.   Gynecology Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gynecology Cancers
        2. Endometriosis
        3. Female Infertility
        4. Menopausal Disorder
        5. Gynecology Infections
        6. Polycystic Ovary Syndrome
        7. Contraception (Birth Control)
        8. Others

  • 9.   Gynecology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 10.   North America Gynecology Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Gynecology Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Gynecology Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Gynecology Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •    1. F. Hoffmann-La Roche Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi, Amgen Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Amgen Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. AstraZeneca, Pfizer, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lupin Pharmaceuticals, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Eli Lilly and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson and Johnson
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Bayer AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Allergan Plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MerckCo.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pfizer, Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients